The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C. (Q34588247)

From Wikidata

Revision as of 23:08, 22 August 2023 by Emijrpbot (talk | contribs) (‎Changed label, description and/or aliases in pt, pt-br, da, fr: BOT - Fixing descriptions (4 languages): da, fr, pt, pt-br)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C. (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

chronic hepatitis

1 reference

based on heuristic

inferred from title

17

object named as

Bruce A Barton

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Jean P. Molleston

4

object named as

Jean P Molleston

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

author name string

Kathleen B Schwarz

1

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Regino P Gonzalez-Peralta

2

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Karen F Murray

3

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Barbara A Haber

5

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Maureen M Jonas

6

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Philip Rosenthal

7

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Parvathi Mohan

8

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

William F Balistreri

9

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Michael R Narkewicz

10

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Lesley Smith

11

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Steven J Lobritto

12

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Stephen Rossi

13

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Alexandra Valsamakis

14

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Zachary Goodman

15

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Patricia R Robuck

16

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Peds-C Clinical Research Network

18

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

language of work or name

0 references

publication date

28 October 2010

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Gastroenterology

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

140

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

450-458.e1

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Mechanism of action of ribavirin in the treatment of chronic hepatitis C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042126

7 July 2018

Ophthalmologic complications in children with chronic hepatitis C treated with pegylated interferon

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042126

7 July 2018

High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042126

7 July 2018

Diagnosis, management, and treatment of hepatitis C: an update

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042126

7 July 2018

Impact of Hepatitis C Virus Infection on Children and Their Caregivers: Quality of Life, Cognitive, and Emotional Outcomes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042126

7 July 2018

Assessing ribavirin exposure during pregnancy: the Ribavirin Pregnancy Registry

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042126

7 July 2018

Efficacy and safety of peginterferon-alpha2b and ribavirin combination therapy in children with chronic hepatitis C infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042126

7 July 2018

Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C Trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042126

7 July 2018

Design of the PEDS-C trial: pegylated interferon +/- ribavirin for children with chronic hepatitis C viral infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042126

7 July 2018

Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042126

7 July 2018

Optimal therapy of hepatitis C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042126

7 July 2018

Recombinant alfa-interferon plus ribavirin therapy in children and adolescents with chronic hepatitis C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042126

7 July 2018

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042126

7 July 2018

An analysis of published trials of interferon monotherapy in children with chronic hepatitis C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042126

7 July 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042126

7 July 2018

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042126

7 July 2018

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042126

7 July 2018

Teratogenic effects of ribavirin on hamster and rat embryos

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042126

7 July 2018

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042126

27 October 2018

Pegylated interferon and ribavirin-induced depression in chronic hepatitis C: role of personality

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042126

27 October 2018

Long-term course of chronic hepatitis C in children: from viral clearance to end-stage liver disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042126

27 October 2018

Safety, efficacy and pharmacokinetics of peginterferon alpha2a (40 kd) in children with chronic hepatitis C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042126

27 October 2018

The natural history of hepatitis C virus in pediatric liver transplant recipients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042126

27 October 2018

The burden of hepatitis C virus infection in children: estimated direct medical costs over a 10-year period

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042126

27 October 2018

Liver histology and alanine aminotransferase levels in children and adults with chronic hepatitis C infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042126

27 October 2018

Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042126

27 October 2018

Three broad modalities in the natural history of vertically acquired hepatitis C virus infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042126

27 October 2018

Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042126

27 October 2018

Embryotoxic, teratogenic, and metabolic effects of ribavirin in mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042126

27 October 2018

Understanding social stigma in women with hepatitis C

1 reference

https://pubmed.ncbi.nlm.nih.gov/21036173

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hepatocellular carcinoma in 2 young adolescents with chronic hepatitis C

1 reference

https://pubmed.ncbi.nlm.nih.gov/21036173

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1053/J.GASTRO.2010.10.047

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34588247&oldid=1959054380"